CDTX
USDCidara Therapeutics Inc. Common Stock
Real-time Price
Price Chart
Key Metrics
Market Metrics
Open
$51.437
High
$52.330
Low
$47.690
Volume
1.24M
Company Fundamentals
Market Cap
1.1B
Industry
Biotechnology
Country
United States
Trading Stats
Avg Volume
0.57M
Exchange
NCM
Currency
USD
52-Week Range
Related News
JMP Securities Maintains Market Outperform on Cidara Therapeutics, Maintains $59 Price Target
JMP Securities analyst Roy Buchanan maintains Cidara Therapeutics with a Market Outperform and maintains $59 price target.
Cidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today
Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. ("Cidara") (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics,
Cidara Announces Pricing of Upsized Public Offering of Common Stock
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. ("Cidara") (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics,
RBC Capital Maintains Outperform on Cidara Therapeutics, Raises Price Target to $75
RBC Capital analyst Brian Abrahams maintains Cidara Therapeutics with a Outperform and raises the price target from $35 to $75.
Guggenheim Maintains Buy on Cidara Therapeutics, Raises Price Target to $68
Guggenheim analyst Seamus Fernandez maintains Cidara Therapeutics with a Buy and raises the price target from $50 to $68.
Cidara Announces Proposed Public Offering of Common Stock
SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. ("Cidara") (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics,
Related Stocks
Stay Updated
Set price alerts, get AI analysis updates and real-time market news.